Shortly after we made a diagnosis of bullous pemphigoid in this minipig, we found that a second minipig in the colony had similar, but less severe, lesions. Again, we did not administer ...

As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...

The supplemental biologics license application for Dupixent for the treatment of bullous pemphigoid in adults ... is driven by type 2 inflammation which causes blisters and rashes to form on ...

Dupilumab, an interleukin-4 receptor antagonist, is expected to decrease the type 2 inflammation seen in bullous pemphigoid.

Patients treated with on dupilumab showed significant improvement in sustained BP remission compared with those on placebo.

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoidIf approved, Dupixent would be the first and only ...

Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application (sBLA) for Dupixent (dupilumab) to ...

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority ...